| Cullinan Management Inc (CGEM) | |||
|---|---|---|---|
| 10.51 -0.05 (-0.47%) | 03-24 16:00 | ||
| Open: | 10.52 | Pre. Close: | 10.56 |
| High: | 10.68 | Low: | 10.3 |
| Volume: | 142,134 | Market Cap: | 413(M) |
| Stock Technical Analysis | |
|---|---|
| Overall: |  |
| Target: | Six months: 13.13  One year: 13.82 |
| Support: | Support1: 10.30 Support2: 8.57 |
| Resistance: | Resistance1: 11.25 Resistance2: 11.83 |
| Pivot: | 10.98 |
| Moving Averages: | MA(5): 10.66 MA(20): 11.06 MA(100): 11.42 MA(250): 12.04 |
| MACD: | MACD(12,26): -0.15 Signal(12,26,9): -0.07 |
| %K %D: | %K(14,3): 12.30 %D(3): 20.44 |
| RSI: | RSI(14): 41.10 |
| 52-Week: | High: 15.89 Low: 7.3 Change(%): -5.4 |
| Average Vol(K): | 3-Month: 212 10-Days: 386 |
| Prices Prediction (Update @5:00pm) | ||
|---|---|---|
| If tomorrow: | Open lower | Open higher |
| High: | 10.705 - 10.758 | 10.758 - 10.8 |
| Low: | 10.156 - 10.227 | 10.227 - 10.284 |
| Close: | 10.41 - 10.518 | 10.518 - 10.606 |
| Price, MAs and Bollinger Bands |
|---|
| Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CGEM ] has closed above bottom band by 10.5%. Bollinger Bands are 25.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
| Company profile |
|---|
| Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts. |
| Stock chart |
|---|
 |
| Financial Analysis | |
|---|---|
| Price to Book Value: | Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. | |
| Price to Earnings: | Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). | |
| Discounted cash flow: | Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. | |
| Return on Assets: | Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. | |
| Return on Equity: | Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. | |
| Debt to Equity: | Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. | |
| Stock Basics & Statistics | |
|---|---|
| Exchange: NASDAQ Global Select | |
| Sector: Healthcare | |
| Industry: Biotechnology | |
| Shares Out. (M) | 39.33 |
| Shares Float (M) | 22.78 |
| % Held by Insiders | 12.56 |
| % Held by Institutions | 81.50 |
| Shares Short (K) | 2100 |
| Shares Short Prior Month (K) | 1940 |
| Stock Financials | |
|---|---|
| EPS | 2.470 |
| Book Value (p.s.) | 11.680 |
| Profit Margin | |
| Operating Margin | |
| Return on Assets (ttm) | -16.3 |
| Return on Equity (ttm) | 22.7 |
| Qtrly Rev. Growth | |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | -3.306 |
| Qtrly Earnings Growth | |
| Operating Cash Flow (M) | -126.66 |
| Levered Free Cash Flow (M) | -46.35 |
| Stock Valuation | |
|---|---|
| PE Ratio | 4.26 |
| PEG Ratio | |
| Price to Book value | 0.90 |
| Price to Sales | |
| Price to Cash Flow | -3.26 |
| Stock Dividends | |
|---|---|
| Dividend | |
| Dividend Yield | |
| Dividend Growth | |
